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BRIEF REPORT
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intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus
Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and
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ABSTRACT
Background: VPM1002BC is a modified mycobacterium Bacillus Calmette Guérin (BCG) for the treatment
of non-muscle invasive bladder cancer (NMIBC). The genetic modifications are expected to result in
better immunogenicity and less side effects. We report on patient safety and immunology of the first
intravesical application of VPM1002BC in human.
Methods: Six patients with BCG failure received a treatment of 6 weekly instillations with VPM1002BC.
Patients were monitored for adverse events (AE), excretion of VPM1002BC and cytokines, respectively.
Results: No DLT (dose limiting toxicity) occurred during the DLT-period. No grade ≥3 AEs occurred.
Excretion of VPM1002BC in the urine was limited to less than 24 hours. Plasma levels of TNFα
significantly increased after treatment and blood-derived CD4+ T cells stimulated with PPD demon-
strated significantly increased intracellular GM-CSF and IFN expression.
Conclusion: The intravesical application of VPM1002BC is safe and well tolerated by patients and results
in a potential Th1 weighted immune response.
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Introduction
Clinical guidelines for high risk NMIBC recommend com-
plete transurethral resection of the bladder tumor (TURB)
followed by BCG induction and maintenance therapy for at
least one year as the standard therapy.1 In addition to the
prevention of recurrence and progression of NMIBC,2 the use
of BCG as a mean of initiating anti-tumor immunity has also
shown to prolong overall survival as compared to TURB
alone3 and, in combination with maintenance therapy, super-
iority over intravesical chemotherapy.4
Bladder instillation of BCG induces a local infection invol-
ving attachment and internalization of mycobacteria into
healthy and cancerous urothelial cells. Infected urothelial
cells secrete a variety of pro-inflammatory chemokines and
cytokines that attract neutrophils. Activation of the innate
immune system is important for successful therapy and ide-
ally induces a TH1 weighted immune response with induction
of the adaptive immune system in terms of T cell responses.5,6
In case of failure of intravesical BCG therapy, current
guidelines support radical cystectomy. If patients are unwill-
ing or unfit to undergo cystectomy, a second round of BCG
therapy, other immunotherapies, intravesical chemotherapies,
device-assisted therapies, or combination therapies may be
applied. Currently these therapies lack long-term results and
solid prospective validation and are therefore considered
oncologically inferior to cystectomy.1 Only scarce data is
available from prospective studies regarding the outcome of
a second BCG therapy round in patients with BCG failure. Di
Lorenzo, et al. reported on 40 patients receiving BCG re-
induction: 87.5% of patients failed to respond to BCG re-
induction at one year; one patient died of systemic disease,
37.5% of the patients had disease progression and had to
undergo cystectomy and 40% underwent radiation therapy
plus systemic chemotherapy after one year.7
Several attempts of genetic modifications with the goal to
enhance TH1 weighted immune responses in the bladder have
been undertaken.8 One of these genetically modified vaccines,
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VPM1002, is currently tested in vaccine trials for tuberculosis9
and is now being developed as VPM1002BC for intravesical
application.
VPM1002BC is a live, recombinant Mycobacterium bovis
BCG (rBCGΔureC::hly). It was generated to direct phagoso-
mal antigens to the major histocompatibility complex
I pathway and enhance the induction of CD4+ and CD8+
T cell-mediated immune responses.10,11 To this end, the lis-
teriolysin (hly) gene from Listeria monocytogenes was inserted
into the urease C gene (ureC). Urease C activity is aborted by
this insertion and the enzyme is no longer able to stabilize the
pH in the phagosome of the host cell. Consequently, the pH
drops and activates listeriolysin (LLO), which is most active at
pH 5.5. LLO is a hemolysin able to perforate membranes. Its
activity in the phagosome allows proteins to translocate to the
cytosol of infected host or cancer cells.
Due to the unique mode of action, VPM1002BC is
expected to be at least as potent as conventional BCG in
evoking immune responses and should be rapidly cleared
from the host, supporting the idea of lower side effects and
lower systemic toxicity.11–13
Here, we report on the first intravesical application of
VPM1002BC for the treatment of non-muscle invasive blad-
der cancer in patients with initial BCG therapy failure.
Patients and methods
Study design
The trial (NCT02371447) was designed as a multicenter, open-
label, single arm, dose-de-escalation phase I/II study and con-
ducted in compliance with the current version of the Declaration
of Helsinki,14 the ICH-GCP15 and with national legal and regula-
tory requirements. The institutional review board at each partici-
pating center approved the trial. All patients provided written
informed consent prior to enrollment.
Patients included in the trial presented with recurrent
NMIBC with high risk for progression (score 7–23 based on
the European Organization for Research and Treatment of
Cancer scoring system) after BCG therapy, for whom radical
cystectomy was indicated but were unfit or unwilling to
undergo cystectomy. We used the EAU 2008 Guideline defi-
nition of BCG failure to ensure comparability of outcome
with our reference study.7 All patients had histologically con-
firmed diagnosis of recurrent NMIBC. A repeat TURB con-
firming a tumor-free state was mandatory, except for
carcinoma in situ (CIS). In patients presenting with CIS,
selective upper tract cytologies and biopsies of the prostatic
urethra were recommended. At the start of the planned treat-
ment, cytology by bladder wash had to be negative, except for
patients with concomitant CIS.
Exclusion criteria for the trial were stage ≥ T2 urothelial
carcinoma of the bladder, concomitant urothelial carcinoma
of the upper urinary tract, or non-prostatic urethra. The
detailed inclusion and exclusion criteria can be found here
(Hyperlink: https://clinicaltrials.gov/ct2/show/NCT02371447).
The primary endpoint was defined as the occurrence of DLT
of intravesical VPM1002BC instillations. The DLT period was
defined as the time for the first three instillations plus one
week. DLTs were defined as Common Terminology Criteria
for Adverse Events (CTCAE) grade 3 events related to the
trial treatment and persisting more than 12 days despite
adequate supportive measures or CTCAE ≥ grade 4 events
related to trial treatment occurring during the DLT period.
The secondary endpoint was the tolerability of the intravesical
instillation of VPM1002BC. Tolerability during induction
phase was defined as finishing at least five instillations of
VPM1002BC within 12 weeks after treatment initiation.
A dose de-escalation and not a dose escalation design was
chosen based on the regular starting dose of BCG (1–20 × 108
CFU BCG/50 ml NaCl).1 The 3 + 3 dose de-escalation strategy
defined dose level 1 at 1–19.2 × 108 CFU/50 ml and dose level
−1 at 1–19.2 × 107 CFU/46.4 ml.
Patients were scheduled for a standard treatment of six
weekly instillations with VPM1002BC, followed by
a maintenance regimen of one year with three weekly instilla-
tions at 3, 6 and 12 months after start of treatment.
Patients
Between September 2015 and May 2016, six patients were
included into the trial at two Swiss centers. Patient character-
istics are summarized in Table 1.
Excretion profile of VPM1002BC
Blood and sputum samples were collected approximately
one hour before instillations and at 24 hours after instillations
Table 1. Patient baseline characteristics.
Variable Total (N = 6) n (%)
Age at registration (years) 74.0 (min. 71.0, max. 82.0)
Sex
Male 6 (100.0%)
WHO performance score
0 6 (100.0%)
1973 WHO grading
Grade 2: moderately differentiated 1 (16.7%)
Grade 3: poorly differentiated 5 (83.3%)
2004 WHO grading
High-grade urothelial carcinoma 6 (100.0%)
Current T classification after last TURB
pT0 3 (50.0%)
pTis 3 (50.0%)
Current N classification after last TURB
cN0 6 (100.0%)
Current M classification after last TURB
cM0 6 (100.0%)
T classification for recurrence in bladder
pTa 1 (16.7%)
pT1 2 (33.3%)
pTis 3 (50.0%)
N classification for recurrence in bladder
cN0 6 (100.0%)
M classification for recurrence in bladder
cM0 6 (100.0%)
T classification for recurrence in prostatic urethra
pT0 4 (66.7%)
pTX 2 (33.3%)
Localization of the tumor at recurrence (more than one applicable)
Anterior wall 2 (33.3%)
Dome 2 (33.3%)
Left wall 2 (33.3%)
Posterior wall 1 (16.7%)
Prostatic urethra 0 (0.0%)
Right wall 3 (50.0%)
Trigone and neck of the bladder 1 (16.7%)
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1 and 6. Urine samples were collected before instillation 1 and
6, and 2, 4, 8 and 24 hours after instillations 1 and 6.
Urine and sputum samples were decontaminated with
N-acetyl-L-cystein-NaOH as described previously16 to avoid
bacterial overgrowth. Heparin blood was analyzed without
decontamination. The resuspended sample was then used for
quantitative mycobacterial culture as well as M. tuberculosis
complex (MTB)-specific in-house real-time PCR.16
Quantitative mycobacterial culture consisted of ten-fold dilu-
tions of the sample up to 1.0 × 10−6. For resuspension and
dilution, sterile PBS buffer plus 0.05% Tween-80 was used.
Hundred microliters of each dilution were inoculated in tri-
plicates on 7H10 agar plates. The plates were stored in an
incubator at 37°C for six weeks and read weekly to enumerate
the CFU. In addition, 1 ml of heparin blood was inoculated in
BACTEC™Myco/F Lytic medium (Becton Dickinson) and
incubated for six weeks in a BACTEC 9050 unit. Cultured
isolates were identified and confirmed as VPM1002BC using
a VPM1002BC hly-specific conventional PCR (35 cycles, PCR
product length: 1415 bp) developed by Vakzine Projekt
Management GmbH, Hannover, Germany.
Cytokine measurement in blood and urine
Kinetics of individual cytokine production by blood cells and
in the urine taken before and after VPM1002BC treatments
were analyzed. Urine samples were taken before instillation 1
(H0), and 4 hours (H4) after instillations 1, 3 and 6 of the
induction phase and frozen immediately. Blood from patients
was taken before instillations 1, 3 and 6 using TruCulture®
(Myriad RBM, Austin, TX, USA) tubes containing, Mtb
Purified Protein derivative (PPD; Staten Serum Institute,
Copenhagen, Denmark). Staphylococcal Enterotoxin B (SEB;
Bernhard-Nocht-Institut, Hamburg, Germany) and medium
(Myriad RBM, Austin, TX, USA) only served as positive and
negative controls, respectively. After 24 h at 37°C on a dry
heat block, the supernatants were separated from the cells
with a valve and stored at −20°C. Concentrations of IL-2,
IFNγ, TNFα, IL-17, GM-CSF and IL-13 were quantified in
supernatants and urine using a multiplexed particle-based
flow cytometric assay (Bioplex, Bio-Rad Laboratories,
Hercules, CA, USA) according to manufacturer’s instructions
and acquisition performed using a Luminex 100 (Luminex
Corporation, Austin, TX, USA). Creatinin was measured in
urines for volume adjustment.17
Mtb-PPD-specific T cell response
Blood samples were taken before instillations and during
induction at instillations 1, 3 and 6 and during the three
maintenance cycles at instillations 1 and 3. Peripheral blood
mononuclear cells (PBMC) were separated on a density gra-
dient using Vacutainer CPT (Becton, Dickinson and
Company, Franklin Lakes, NJ, USA), washed and stored in
liquid nitrogen until analysis. PBMCs were thawed and cul-
tured (3 × 105 cells per well in duplicates) in 96 U-bottom well
PP plate in presence of 2.5 μg/ml PPD, SEB or unstimulated
(NS) as positive and negative controls, respectively. After six
days, cells were re-stimulated 4 h with PMA/ionomycin
(Sigma-Aldrich), 5 ng/ml and 500 ng/ml respectively, in pre-
sence of brefeldin A (BFA, 10 μg/mL). Cells were stained for
viability (LiveDead-Aqua, Thermo Fisher Scientific, Waltham,
MA, USA) then fixed (FACS Lysing Solution, Beckton,
Dickenson and Company) and stored at −80°C. After permea-
bilization (BD Cytofix/CytopermTM), cells were labeled with
fluorescently labeled antibodies to identify subsets and deter-
mine cytokine expression (Supplementary Methods).
Statistical analyses
Continuous variables were summarized using median and
range, categorical variables using frequency and percentage.
Adverse events were assessed according to NCI CTCAE v4.0.
For the exploratory immunology measurements the differ-
ences to pre-treatment were calculated and illustrated graphi-
cally using line plots.
For the VPM1002BC-specific T cell responses the area
under the curve (AUC) of the differences to pre-treatment
was calculated for each patient and cytokine. The median
AUC and corresponding 95% confidence interval was calcu-
lated and compared to 0 using Wilcoxon signed-rank tests.
Two-tailed tests with a significance level of 0.05 were used
for all analyses. Because no adjustment for multiple testing for
these analyses was made, they were exploratory and hypoth-
esis generating. All analyses were performed using SAS 9.4
(SAS Institute Inc., Cary, NC, USA) and R 3.4.3 (http://www.
r-project.org).
Results
Patients
Adverse events during the induction phase are listed in Table 2.
No CTCAE grade ≥ 3 adverse events (AE) occurred during
induction phase. CTCAE grade 2 AEs were observed in 4 out
of 6 patients. The grade 2 AEs mainly consisted of asymptomatic
urinary tract infections. All but one urinary tract infection (UTI)
presented without symptoms and were detected and treated due
to routine urine cultures taken in the context of the trial setting.
The symptomatic UTI presented in one patient with prostatitis
and did not lead to a stop of trial treatment.
One case of grade 2 decreased GFR was observed. The
patient who experienced this AE presented with chronic kid-
ney disease grade 1 at baseline and the kidney function recov-
ered to baseline after treatment.
No DLT-defining AE occurred in the first three patients
during the DLT period as assessed by an independent safety
committee. Consequently, patients 4–6 were treated at the
same dose level 1. Again, no DLT occurred in these patients.
All patients concluded all six intravesical instillations
within a median duration of 5.8 weeks (min. 5.0 weeks, max
7.1 weeks). Based on these results, the independent safety
committee considered intravesical instillations with
VPM1002BC to be safe and well tolerated.
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Excretion profile of VPM1002BC
Blood, urine and sputum samples were collected to analyze
putative routes of transmission and of intracorporal persistence
of VPM1002BC. All blood and sputum samples, as well as all
urine samples before the first and the sixth instillation showed
no growth and no DNA of VPM1002BC (Figures 1 and 2).
VPM1002BC DNA was detectable 24 hours after instillation 1
and 6 (Figure 2). However, no cultivable bacteria were detectable
24 h after the respective instillations (Figure 1). All isolated
bacteria were characterized by VPM1002BC hly-specific PCR
and all cultured isolates were indicative of VPM1002BC except
for one patient. In this patient, the urine culture after 4 and
8 hours of the first instillation identified conventional BCG
mycobacteria.
Exploratory immunology
Cytokines (IL-2, IFNγ, TNFα, IL-17, GM-CSF and IL-13)
were measured in urines pre and post instillations and in
plasma after stimulation of whole blood with PPD. After the
first instillation, levels of all cytokines in urines increased by
a median factor of 4.9 [range 1.93; 9.63] (Supplementary
Figure 1) and, prior to the third instillation, the levels of
Th1 cytokines (IL-2, IFNγ and TNFα) in plasma increased
by a factor of 1.64 [range 1.63; 1.65] (Supplementary
Figure 2). Of note, TNFα increase in plasma was signifi-
cant (p = .03).
VPM1002BC-specific T cell responses from PBMCs were
assessed by flow cytometry by measuring frequencies of T cell
subsets expressing cytokine (IFNγ, TNFα, IL-17, GM-CSF,
and IL-2) and proliferating (Ki67+) after stimulation with
PPD. Analysis of the kinetics of proliferating cells showed
a significant increase of GM-CSF+ Ki67+ CD4+ T cells after
the first instillation (p = .0313) with a trend for IFNγ (p = .06)
(Supplementary Figure 4). Furthermore, analysis of total
CD4+ T cell responses after PPD showed a significant increase
of IFNγ+ and GM-CSF+, and a trend for IL-17+ CD4+ T cells,
compared to the pre-treatment status over the course of the
induction treatment period (Figure 3). The same analysis of
the CD3+ and CD8+ T cells and the pos. control stimulation
with SEB did not reveal any significant changes over time
(Supplementary figures 4–9).
Discussion
We report the phase I results of the first intravesical applica-
tion of VPM1002BC for the treatment of cancer. VPM1002BC
Table 2. Adverse events during induction phase with VPM1002BC graded according to common terminology criteria for adverse events (CTCAE) Version 4.0.
CTCAE SOC Term Grade 1 n (%) Grade 2 n (%)
Blood and lymphatic system disorders Anemia 2 (33.3%)
Gastrointestinal disorders Abdominal pain 1 (16.7%)
Infections and infestations Asymptomatic bladder infection 1 (16.7%)
Prostate infection 1 (16.7%)
Asymptomatic urinary enterococcus faecalis 1 (16.7%)
Asymptomatic urinary tract infection 1 (16.7%)
Investigations Creatinine increased 1 (16.7%)
Nervous system disorders Headache 1 (16.7%)
Renal and urinary disorders Alguria 2 (33.3%)
Decreased GFR/Chronic kidney disease* 1 (16.7%)
Hematuria 1 (16.7%)
Nycturia 1 (16.7%)
Skin and subcutaneous tissue disorders Temporary redness of the skin 1 (16.7%)
Vascular disorders Hematoma 1 (16.7%)
* grade 1 at baseline.
Figure 1. Colony forming units (cfu) of VPM1002BC in urine after the first
intravesical VPM1002BC instillation (blue dots) and the 6th intravesical
VPM1002BC instillation (red squares).
Figure 2. Cycle threshold (ct) values of VPM1002BC PCR in urine measured 2, 4,
8 and 24 hours after the first intravesical VPM1002BC instillation (blue dots) and
the 6th intravesical VPM1002BC instillation (red squares). Ct-values > 45 were
set as 45 in the figure.
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was well tolerated and no DLT occurred during the treatment.
All patients were able to finish the 6 weekly instillations of
VPM1002BC and within the predefined timeframe. The grade
2 adverse finding of asymptomatic urinary tract infections in
3 out of 6 patients as well as prostatitis in 1 out of 6 patients
needs further attention during the phase II of the study.
However, asymptomatic bacteriuria is a common finding dur-
ing BCG therapy and has been reported in up to 30% of the
treated patients.3 Regarding the single case of grade 2
impaired renal function the affected patient presented with
chronic kidney disease grade 1 at baseline and like all patients
undergoing BCG therapy was asked not to drink in the
morning prior to the instillation. This may have resulted in
lowered pre-treatment estimated GFR values that resolved
after treatment.
To assess putative routes of transmission of VPM1002BC
into the environment as well as persistence in the body, urine,
blood and sputum were collected and analyzed by the CFU
counts method and by MTB PCR. In all these samples of the
six patients, no traces of VPM1002BC DNA and no CFU of
VPM1002BC before the initial and before the 6th instillation
were detected. This analysis showed no persistence of
VPM1002BC 24 hours after the sixth instillation in the
urine. In one patient, culture of conventional BCG in the
urine was obtained at the first instillation. This is indicative
of a persistence of conventional BCG of 6.6 months after the
Figure 3. Intracellular cytokine expression in peripheral blood mononuclear cell (PBMC) derived CD4+ T cells after re-stimulation with purified protein derivative
(PPD). Patient-derived CD4+ T cells from PBMCs before (I1 = instillation 1), and during the course of the induction phase (I3, I6) were assessed for the indicated
intracellular cytokine concentrations. The colored lines depict the individual development per patient. Fold-changes compared to the pre-treatment status (I1) of the
percentage of CD4+ T cells producing the cytokine of interest are shown.
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preceding BCG therapy cycle. Such long lasting persistence
has been reported before in bladder granulomas after conven-
tional BCG treatment.18 A previous study demonstrated CFUs
in up to 40% of patients treated with BCG Connaught strain
after 24 h and after 6 days in 27.1% of patients. A positive
polymerase chain reaction was evident up to 24 months post
instillation in between 4.2% and 37.5% of the investigated
bladder biopsies.18 It’s likely that the implemented genetic
changes in VPM10002BC with increased exposure of myco-
bacterial antigen by perforation of the phagosome
membrane11 leads to quicker clearance of the bacteria from
the bladder.
The analysis of blood and sputum before and after intra-
vesical instillations of VPM1002BC showed no CFUs and no
traces of VPM1002BC DNA. As such, a systemic uptake of
VPM1002BC could not be demonstrated in the study setting.
In order to gain preliminary insight into the immune
responses induced by VPM1002BC in the treated patients,
cytokines in urine and in whole blood were determined.
Despite the limited sample size (6 patients) and the sample
variability, a clear trend in TH1 cytokines induction was
observed both in urine and whole blood in a global analysis
of cytokine secretion with a significant induction of TNFα in
whole blood (Supplementary Figure 1 and 2). Furthermore,
responses to PPD either from whole CD4+ or Ki67+CD4+
T cells were significant for GM-CSF and IFNγ. Our data is
in agreement with previous findings. It has been indeed
demonstrated that TNFα may play an ambiguous role since
it was associated with tumor growth and poor prognosis,19
but also increased in urine of patients undergoing BCG treat-
ment. In this regard, urinary neutrophils, strongly induced
during BCG treatment, express large amounts of TNFα.20
Moreover, under the stimulation of INFγ, TNF-related apop-
tosis-inducing ligand (TRAIL), a member of the TNFα family,
expressed by a number of cells such as macrophages, dendritic
cells, natural killer cells, B cells and T cells is able to confer to
these cells enhanced anti-tumor abilities.21 Finally, TNFα and
GM-CSF were characterized in recent studies as playing a role
in the prevention of bladder cancer.22 Taken together, our
data, including a trend in IL-17 secretion by PBMC,
a cytokine also associated by some authors to the recruitment
of neutrophils after BCG treatment, brings arguments for
VPM002BC in reproducing some aspects of the immunologi-
cal cascade induced by BCG. Although the role of TNFα,
IFNγ, IL-17 and GM-CSF cannot be definitively established
at that stage, it could be of interest to postulate that these TH1
cytokines may play a role in the anti-tumor effect of
VPM1002BC. Furthermore, in subsequent efficacy trials, it
would be interesting to examine the variations of these cyto-
kines as markers of protection. Elsäßer, et al. reported that
IFNγ-producing CD4+ T cells of patients with a preexisting
immunity against BCG increased to a much lesser extent as
compared to BCG-naive patients.23 Since all patients included
in the trial already experienced a previous BCG treatment
course, the clear increase in the frequency of these cells in
our trial is interesting and potentially indicative for the induc-
tion of an immune response by VPM1002BC. A more detailed
analysis on a larger number of patients will be assessed in the
phase II of the trial in order to corroborate these results.
Conclusion
The intravesical application of VPM1002BC is safe, well tol-
erated by the patients and shows promising immunological
results. Phase II of this trial with the aim to test the prelimin-
ary efficacy in BCG-non-responding patients has completed
recruitment and final results are expected for 2019.
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